Tidewater Inc vs GeneDx Holdings Corp — how do they compare? Tidewater Inc trades at $78.18 (market cap $3.75B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Tidewater Inc is far larger — about 2.1× GeneDx Holdings Corp's market cap, and Tidewater Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| TDW | WGS | |
|---|---|---|
Market Cap | $3.75B | $1.80B |
Sector | Utilities | Technology |
52-Week High | $91.12 | $167.51 |
52-Week Low | $47.29 | $34.51 |
Enterprise Value | $3.85B | $1.80B |
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings show mixed results, missing Q1 2026 estimates with $0.12 EPS versus $0.75 expected. The company maintains strong profitability with a 22.16% net margin and 24.03% ROE, while valuation ratios like a P/E of 12.72 suggest potential undervaluation. News highlights include the acquisition of Tidewater Logistics by FTAI Infrastructure in June 2026.
The outlook is cautiously optimistic due to solid fundamentals and analyst buy ratings, but risks include earnings volatility and sector sensitivity. Upside potential hinges on execution improvements, while downside risks stem from energy market fluctuations and competitive pressures.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Trailing returns across standard periods
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →